Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

D Mannose in Recurrent Urinary Tract Infections

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01808755
Recruitment Status : Completed
First Posted : March 11, 2013
Results First Posted : May 21, 2014
Last Update Posted : May 21, 2014
Sponsor:
Information provided by (Responsible Party):
Daniele Porru, IRCCS Policlinico S. Matteo

Brief Summary:

Background- In recurrent urinary tract infections (RUTIs) usual prophylactic antibiotic regimes do not change the long term risk of recurrence.

Objective- D-Mannose is a sugar, it sticks to E. coli bacteria, the aim of the study was to evaluate its efficacy in the treatment and prophylaxis of recurrent UTIs.

Design, setting and participants- : In this crossover trial female patient were eligible for the study if they had recurrent UTIs, that is three ore more episodes during the preceding 12 months. Suitable patients were randomly assigned to antibiotic treatment with trimethoprim/sulfamethoxazole or to a regimen of oral D Mannose for 24 weeks, and received the other intervention in the second phase of the study.

Outcome measurements and statistical analysis- The time to recurrence of UTI, bladder pain (VAS p) and urinary urgency (VAS u) were evaluated at the end of antibiotic therapy and at the and of 24 weeks fo D Mannose. The results for quantitative variables were expressed as mean values and SD as they were all normally distributed (Shapiro-Wilk test). T-test for paired data was used to analyze differences of time of recurrence, VAS pain, Vas urgency and number of voidings between treatment. Data analysis was performed with STATA statistical package (release 11,1, 2010, Stata Corporation, College Station, Texas, USA).


Condition or disease Intervention/treatment Phase
Recurrent Urinary Tract Infection Dietary Supplement: D Mannose Drug: trimethoprim/sulfamethoxazole Phase 3

  Hide Detailed Description

Detailed Description:

INTRODUCTION Urinary tract infections (UTIs) are among the most common infectious diseases, with a substantial financial burden to society. In Europe data on the presence of various types of UTIs indicate a high impact on quality of life of people affected, it is important the impact of urinary tract infections on the economy in general and on the health system in particular. In the U.S. urinary tract infections account for more than 7 million doctor visits each year, including more than 2 million visits for cystitis. The bacterium E. coli, which is the source of 90% of urinary tract infections, shows an incredible ability to survive in the human body, and is able to change rapidly to survive antibiotics. An infection of the urinary tract must be stopped before it begins to migrate to the kidneys, where it can cause serious infections. Women with frequent reinfections have a rate of 0.13 to 0.22 UTIs per month (1.6 to 2.6 infections per year). For premenopausal, healthy, and active females, recurrent UTIs are a major healthcare concern. Recurrent urinary tract infection (RUTI) is defined as three episodes of urinary tract infection (UTI) with 3 positive urine cultures in the previous 12 months or two episodes in the last six months. The usual present strategies employing a prophylactic antibiotic regime to prevent recurrent UTIs include long-term low-dose prophylactic antimicrobial treatment or postcoital antibiotic treatment. However, it seems that these strategies do not alter the long-term risk of recurrence. Patients with frequent UTIs who take prophylactic antimicrobial agents for extended periods decrease their infections during prophylaxis, but the rate of infection returns to pre-treatment rates when prophylaxis is stopped . Long-term antibiotics do not appear to positively affect the patient's basic susceptibility to infections. The cell wall of E. coli bacteria has tiny finger-like projections that contain complex molecules called lectins on their surface. These lectins act as a cellular glue that binds the bacteria to the bladder wall so they cannot be easily rinsed out by urination . In this pilot study the aim was to evaluate if oral D Mannose could be used as a safe and effective treatment and as a prophylactic measure for recurrent UTIs in adult women.

PATIENTS AND METHODS Suitable female patients with recurrent urinary tract infections who were visited at the outpatient Clinic of our Urology Department were eligible for study. The work has been conducted in accordance with the principles of the Declaration of Helsinki of World Medical Association. Patients were enrolled in the study after treatment for the most recent urinary tract infection if they had positive urinary cultures at that time.

Each participant entering the trial was assigned to one of the following treatments in a random sequence:

  1. A regimen of five-day antibiotic therapy with trimethoprim/sulfamethoxazole 160 mg/800 mg twice a day. Then 1 week of antibiotic every 4 weeks for the following 23 weeks
  2. A regimen of oral D Mannose 1 gr. 3 times a day, every 8 hours for 2 weeks, and subsequently 1 gr. twice a day for 22 weeks. D-Mannose has the best activity when urine has neutral pH, therefore patients were instructed to measure urinary pH using dipsticks and use oral sodium bicarbonate 250 mg b.i.d.or potassium citrate 1 gr. b.i.d. as alkalinizing agents if pH was <7.

Patients were randomly assigned to antibiotic treatment with trimethoprim/sulfamethoxazole or to a regimen of oral D Mannose for 24 weeks, and received the other intervention in the second phase of the study.

VAS score for bladder pain (VASp) and for urgency (VASu) was evaluated before starting D Mannose and at 24 weeks. The 24 hour number of voidings was obtained filling a voiding diary before and at the end of treatment with D Mannose. Cure was defined as the resolution of symptoms and no post-treatment bacteriuria at the 24 week follow-up visit. Cure with recurrence was defined as having resolution of symptoms with negative cultures at 12 week followed by significant UTI with bacteriuria before 24 weeks. Failure was defined as having persistent symptoms and significant bacteriuria before 24 weeks. The cure rate was determined for patients who met infection criteria, returned for the follow-up visits and had been treated with an antimicrobial for recurrent urinary tract infection occurring twice or more times during the 6 months preceding the 24 weeks course of daily oral D Mannose. The time to recurrence of UTI, VAS pain and VAS urgency were evaluated at the end of antibiotic therapy and at the end of 24 week treatment with oral D Mannose. Statistical Analysis- The results for quantitative variables were expressed as mean values and SD as they were all normally distributed (Shapiro-Wilk test). T-test for paired data was used to analyze differences of time of recurrence, VAS pain, Vas urgency and number of voidings between treatment. Data analysis was performed with STATA statistical package (release 11,1, 2010, Stata Corporation, College Station, Texas, USA).

DISCUSSION- The approach in the management of recurrent urinary tract infections is usually to treat adequately an episode of infection and after the completion should document complete eradication with a urine culture; if infection reoccurs or persists then imaging is required. In the management of recurrent UTIs in women it is a common practice to fight the resistance of the bacterium E. coli by varying the type of antibiotics, or increasing the dose and duration of therapy. However, in doing so the bacteria become even more resistant to broad spectrum antibiotics. Moreover, the resistance of the bacterium would not increase if the infection was due to a new E. coli contamination of the faeces or to sexual contact. What actually appears to occur is the survival of a part of the old colony of bacteria in the urinary tract, they remain latent and are reactivated by various favourable conditions, the relentless recurrences are therefore not considered as reinfection. It could be learnt a lot from patients and from research done on the causes of repeated urinary tract infections, especially due to the bacterium E. coli. Uropathogenic Escherichia coli (UPEC) strains may contain virulence factors that allow the bacteria to penetrate into the transitional cells and form quiescent intracellular reservoirs (QIRs). Establishment of QIRs throughout the underlying transitional epithelium may predispose an individual to an increased likelihood of recurrence and may account for some of the frequent same-strain recurrences that are seen clinically despite appropriate antibiotic therapy. A difficult aspect of treating urinary tract infections in women is the high likelihood of recurrence. In a series of trials a group of susceptible women averaged 2.6 infections per patient per year despite the apparent effectiveness of short-term therapy. While long-term prophylaxis was relatively effective in that series, resistance to trimethoprim-sulfamethoxazole by urinary pathogens increased to 19% in a 5-year period. Although there is debate regarding the duration of antibiotic therapy, emergence of drug-resistant organisms has to be considered with prolonged antibiotic use, even in healthy women with uncomplicated UTIs. A number of triggers lead to the reactivation of dormant E.coli already in the bladder, or the release of E.coli pods from behind biofilms in the bladder. When a first UTI is caused by E. coli, the risk of a second infection within 6 months is greater than when a first infection is cause by another uropathogen. Although E. coli was the most frequently isolated microorganism in our group of patients, the limited number of patients studied could not confirm this assumption. The chemical structure of D-Mannose causes it to stick to E. coli bacteria, maybe even more tenaciously than E. coli adheres to human cells. Although the mechanism of how it works is complicated, theoretically, if enough D-mannose is present in the urine, it binds to the bacteria and prevents them from attaching to the urinary tract lining. Our clinical experience shows that D Mannose represents a useful choice to address the problem of recurrent UTIs. The time required to develop a new infection, or for the re-emergence of the bacterial reservoir, as can be assumed from new data, is significantly longer with a prolonged course of oral D Mannose than with antibiotic treatment, even when these are used for long periods at a low dose, or in cycles. We actually know mannose has no bactericidal properties, and it might well be that the dosage and duration of therapy have to be individualized according to bacterial growth and replication speed in the bladder and urinary tract. The major part of mannose ingested is eliminated with urine and works by binding to bacteria concentrated in infected urine and attempting to perpetuate infection by binding to mannose receptors of urothelial bladder cells, this mechanism being the one involved in most cases of recurrences. In most cases recurrences are wrongly regarded as re-infections: it is highly likely that bactericidal molecules not possessing the same properties cannot produce the same consistent effect, that is the elimination of more and more loads of bacteria with urine, "alive" albeit inactivated, motionless, devoid of pathogenic potential due to mannose linked to them.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Recurrent Urinary Tract Infections in Adult Women: a Pilot Study With Oral D Mannose
Study Start Date : January 2012
Actual Primary Completion Date : October 2012
Actual Study Completion Date : October 2012

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: D Mannose
1 gr. every 8 hours for 2 weeks, subsequently 1 gr. every 12 hours for 22 weeks
Dietary Supplement: D Mannose
1 gr. every 8 hours
Other Name: sugar

Drug: trimethoprim/sulfamethoxazole
one cp b.i.d. for 5 days. Then one week of antibiotic every 4 weeks for the following 23 weeks
Other Name: trimethoprim/sulfamethoxazole 160 mg/800 mg

Active Comparator: trimethoprim/sulfamethoxazole
intervention was a 5-days course of trimethoprim/sulfamethoxazole cp 160 mg/800 mg twice a day. Then one week of antibiotic every 4 weeks for the following 23 weeks
Dietary Supplement: D Mannose
1 gr. every 8 hours
Other Name: sugar

Drug: trimethoprim/sulfamethoxazole
one cp b.i.d. for 5 days. Then one week of antibiotic every 4 weeks for the following 23 weeks
Other Name: trimethoprim/sulfamethoxazole 160 mg/800 mg




Primary Outcome Measures :
  1. Days [ Time Frame: 168 ]
    time required to develop the next urinary tract infection; evaluation by means of urine analysis and urine culture



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients 18 years old or older
  • 3 or more culture documented urinary tract infections in the preceding 12 months
  • Patients who had not taken antimicrobials within 4 weeks and were not pregnant or contemplating pregnancy.

Exclusion Criteria:

  • Patients with evidence of upper urinary tract infection, such as temperature higher than 38 °C, flank/lumbar pain or tenderness.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01808755


Locations
Layout table for location information
Italy
Urology Department Fondazione IRCCS Policlinico San Matteo
Pavia, Italy, 27100
Sponsors and Collaborators
IRCCS Policlinico S. Matteo
Investigators
Layout table for investigator information
Principal Investigator: Daniele Porru, MD Urology Dept. Fondazione IRCCS Policlinico San Matteo Pavia

Additional Information:
Publications:
Layout table for additonal information
Responsible Party: Daniele Porru, Consultant Urologist, Principal investigator, IRCCS Policlinico S. Matteo
ClinicalTrials.gov Identifier: NCT01808755     History of Changes
Other Study ID Numbers: DMannose UTIs
First Posted: March 11, 2013    Key Record Dates
Results First Posted: May 21, 2014
Last Update Posted: May 21, 2014
Last Verified: April 2014
Keywords provided by Daniele Porru, IRCCS Policlinico S. Matteo:
recurrent urinary tract infections
D Mannose
cystitis
antibiotic treatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Urinary Tract Infections
Urologic Diseases
Anti-Bacterial Agents
Trimethoprim
Sulfamethoxazole
Anti-Infective Agents
Anti-Infective Agents, Urinary
Renal Agents
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Folic Acid Antagonists
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Dyskinesia Agents
Cytochrome P-450 CYP2C8 Inhibitors
Cytochrome P-450 Enzyme Inhibitors